Skip to content
Screener

Cytokinetics CYTK Other Income (Expense)

Other Income (Expense) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$61M+112%
Eli Lilly logo
Eli LillyLLY
$269M+399%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$1.72M-6.1%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$2.83M+379%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$2.59M+16.8%
iRhythm Holdings, Inc. logo
iRhythm Holdings, Inc.IRTC
$2.16M-49.8%

Other financials

Income statement

See full
Revenue$28.6M-57.1%
Operating income-$179.2M-60.7%
Net income-$198.8M-47.9%
EPS (diluted)-$1.50-33.9%

Balance sheet

See full
Cash & equivalents$255.3M+241%
Total debt$399.0M+31.2%
Total equity-$173.5M+52.9%
Total assets$1.9B+57.0%

Cash flow

See full
Operating cash flow-$159.8M-24.6%
CapEx$4.3M+4.6%
Free cash flow-$164.2M-24.0%

Valuation

See full
Market cap$10.71B+155%
Enterprise value$10.85B+145%
P/S158.2×+109×

Profitability

See full
Operating margin-1,046.1%+1,858pp
Net margin-1,321.1%+8,702pp
FCF margin-858.2%+1,799pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio6.7×-0.1×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338217
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Operating loss(179,172)(111,506)(362,790)(267,137)
Interest and other expense, net(14,654)(11,084)(29,173)(19,952)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements(20,177)(13,181)(38,993)(27,259)
Interest and other income, net13,94113,00124,96326,702
Change in fair value of derivative liabilities(1,100)3,0004002,600
Change in fair value of liabilities related to RPI Transactions2,400(14,600)800(10,700)
Net loss$(198,762)$(134,370)$(404,793)$(295,746)
Net loss per share — basic and diluted$(1.50)$(1.12)$(3.17)$(2.49)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Cytokinetics's other income (expense)?
Cytokinetics (CYTK) reported other income (expense) of $13.94M in Q2 2026.
How has Cytokinetics's other income (expense) changed year-over-year?
Cytokinetics's other income (expense) increased by 7.2% year-over-year, from $13M to $13.94M.
What is the long-term trend for Cytokinetics's other income (expense)?
Over 3 years (2022 to 2025), Cytokinetics's other income (expense) has grown at a 62.2% compound annual growth rate (CAGR), from $11.34M to $48.42M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Cytokinetics's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude